Clinical trial NCT04615273: A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Official title: foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Growth Hormone Deficiency
Endocrine System Diseases
Hormone Deficiency
Keywords: Human Growth Hormone
hGH
rhGH
GHD
Adult Growth Hormone Deficiency
Long-Acting Growth Hormone
Lonapegsomatropin
Prodrug
Growth Failure
Growth Hormone Replacement Therapy
Sustained Release Growth Hormone
Growth Hormone Deficiency
TransCon hGH
Lead sponsor: Ascendis Pharma A/S
Sponsor class: INDUSTRY
First posted: 2020-11-04
Enrollment: 264
Sex: ALL
Minimum age (years): 23
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Double-blind, placebo-controlled, parallel group with participants randomized into 3 treatment groups (1:1:1); lonapegsomatropin once-weekly, placebo for lonapegsomatropin once-weekly, somatropin daily.
Primary purpose: TREATMENT

Brief summary: A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. A total of 264 adults (males and females) with growth hormone deficiency were included. Randomization occurred in a 1:1:1 ratio (lonapegsomatropin: placebo: daily somatropin product). This is a global trial conducted in, but not limited to, the United States, Europe, and Asia.


Eligibility criteria: Inclusion Criteria

1. Age between 23 and 80 years, inclusive, at screening.
2. Adult Growth Hormone Deficiency (AGHD) Diagnosis Criteria

   * For adult-onset AGHD: documented history of structural hypothalamic-pituitary disease, hypothalamic-pituitary surgery, cranial irradiation, 1-4 non-GH pituitary hormone deficiencies, a proven genetic cause of GHD, or traumatic brain injury (TBI).
   * Participants with childhood-onset GHD must have had GH axis re-assessed at final height.
   * In participants with TBI as a cause of GHD, GHD must be confirmed by GH -stimulation testing performed at least 12 months after the injury.

   A. For all countries except Japan: participants must have satisfied at least one of the following criteria:
   1. Insulin tolerance test: peak growth hormone (GH) \<=5 ng/mL
   2. Glucagon stimulation test according to body mass index (BMI)

      * i. BMI \<=30 kg/m\^2: peak GH \<=3 ng/mL
      * ii. BMI \>30 kg/m\^2: peak GH \<=1 ng/mL
   3. Three or four pituitary axis deficiencies (i.e., adrenal, thyroid, gonadal, and/or vasopressin; not including GH) with insulin-like growth factor-1 standard deviation score (IGF-1 SDS) \<= -2.0 at screening
   4. Macimorelin test: peak GH \<=2.8 ng/mL
   5. Growth hormone releasing hormone (GHRH) + arginine test according to BMI:

      * i. BMI \<25 kg/m\^2, peak GH \<11 ng/mL
      * ii. BMI \>=25-\<=30 kg/m\^2, peak GH \<8 ng/mL
      * iii. BMI \>30 kg/m\^2, peak GH \<4 ng/mL

   B. For Japan only: Participants with AGHD and deficiency of at least one non-GH pituitary hormones need to satisfy one of the following GH stimulation tests. Participants with GHD without additional non-GH pituitary hormone deficiencies with or without and evidence of intracranial structure disorder need to satisfy at least 2 of the following stimulation tests:
   1. Insulin tolerance test: peak GH \<=1.8 ng/mL
   2. Glucagon test: peak GH \<=1.8 ng/mL
   3. Growth Hormone Releasing Peptide-2 (GHRP-2) tolerance test: peak GH \<=9 ng/mL
3. IGF-1 SDS \<= -1.0 at screening as measured by central laboratory.
4. hGH treatment naïve or no exposure to hGH therapy or GH secretagogue for at least 12 months prior to screening.
5. For participants on hormone replacement therapies for any hormone deficiencies other than GH (e.g., adrenal, thyroid, estrogen, testosterone) must be on adequate and stable doses for \>=6 weeks prior to and throughout screening.
6. For participants not on glucocorticoid replacement therapy, documentation of adequate adrenal function at screening defined as: morning (6:00-10:00 AM) serum cortisol \>15.0 mcg/dL (measured at central laboratory) and/or adrenocorticotropic hormone (ACTH) stimulation test or insulin tolerance test with serum cortisol \>18.0 mcg/dL at or within 90 days prior to screening.
7. For males not on testosterone replacement therapy: morning (6:00 - 10:00AM) total testosterone within normal limits for age.
8. On a stable diet and exercise regime at screening with no intention to modify diet or exercise pattern during the trial, i.e., no weight reduction program intended during the trial or within the last 90 days prior to or through screening.
9. No plans to undergo bariatric surgery during the trial.
10. Fundoscopy at screening without signs/symptoms of intracranial hypertension or diabetic retinopathy above stage 2 / moderate or above or any other retinal disease contraindicated to growth hormone therapy. For participants with a diagnosis of diabetes mellitus at screening, this must be documented with a fundus photograph.
11. Able and willing to provide a written informed consent and authorization for protected health information (PHI) disclosure in accordance with Good Clinical Practice (GCP).
12. Serum free thyroxine (fT4) in the normal range at screening as measured by central laboratory.

Exclusion Criteria

1. Known Prader-Willi Syndrome and/or other genetic diseases that may have an impact on an endpoint.
2. Diabetes mellitus at screening if any of the following criteria are met:

   1. Poorly controlled diabetes, defined as HbA1c \>7.5% at screening.
   2. Diabetes mellitus (defined as HbA1c \>=6.5% and/or fasting plasma glucose \>=126 mg/dL and/or plasma glucose \>=200 mg/dL two hours after oral glucose tolerance test) diagnosed \<26 weeks prior to screening
   3. Change in diabetes regimen (includes dose adjustment) within \<90 days prior and throughout screening
   4. Use of any diabetes drugs other than metformin and/or dipeptidyl peptidase-4 (DPP-4) inhibitors for a cumulative duration of greater than 4 weeks within 12 months prior to screening
   5. Diabetes-related complications at screening (i.e., nephropathy as judged by the investigator, neuropathy requiring pharmacological treatment, retinopathy stage 2/moderate and above within 90 days prior to screening or during screening)
3. Active malignant disease or history of malignancy. Exceptions to this exclusion criterion:

   1. Resection of in situ carcinoma of the cervix uteri
   2. Complete eradication of squamous cell or basal cell carcinoma of the skin
   3. Participants with GHD attributed to treatment of intracranial malignant tumors or leukemia, provided that a recurrence-free survival period of at least 5 years prior to screening is documented in the participant's file (based on a Magnetic Resonance Imaging (MRI) result for intracranial malignant tumors)
4. Evidence of growth of pituitary adenoma or other benign intracranial tumor within the last 12 months before screening.
5. Participants with acromegaly without remission / with documented remission less than 24 months prior to screening.
6. Participants with Cushing's disease without remission / with documented remission less than 24 months prior to screening.
7. Participants with prior cranial irradiation or hypothalamic-pituitary surgery: the procedure was to take place less than 12 months prior to screening.
8. Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m\^2 determined based on Modification of Diet in Renal Disease (MDRD) equation.
9. Hepatic transaminases (i.e., aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\]) \>3 times the upper limit of normal.
10. Heart failure New York Heart Association (NYHA) class 3 or greater (NYHA 1994).
11. Q-T interval, corrected by Fridericia's method (QTcF) \>= 451 milliseconds on 12-lead electrocardiogram (ECG) at screening.
12. Poorly controlled hypertension, defined as supine systolic blood pressure \>159 mmHg and/or supine diastolic blood pressure \>95 mmHg at screening.
13. Cerebrovascular accident within 5 years prior to screening.
14. Anabolic steroids (other than gonadal steroid replacement therapy) or oral/intravenous/intramuscular corticosteroids within 90 days prior to or throughout screening.
15. Currently using or have used within 26 weeks prior to screening any weight-loss or appetite-suppressive medications including orlistat, zonisamide, lorcaserin, bupropion, topiramate, sibutramine, stimulants, glucagon-like peptide 1 (GLP-1) receptor agonists, sodium-dependent glucose cotransporters (SGLT-2) inhibitors or medications that affects IGF-1 or GH measurements including cabergoline at doses above 0.5 mg weekly or bromocriptine at doses above 20 mg weekly.
16. Known history of hypersensitivity and/or idiosyncrasy to any of the test compounds (somatropin) or excipients employed in this trial.
17. Known history of neutralizing anti-hGH antibodies.
18. Inability to undergo scanning by dual-energy x-ray absorptiometry (DXA) or a non-interpretable DXA scan at screening.
19. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential (i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile) and not using adequate contraceptive methods.
20. Male participants must use a condom, or his female partner of childbearing potential must use an effective form of contraception as described above, from the beginning of screening to the last trial visit.
21. Known substance abuse or known (or previous) eating disorders, including anorexia nervosa, bulimia and severe gastrointestinal disease affecting normal eating (as judged by the investigator).
22. Any disease or condition that, in the judgement of the investigator, may make the subject unlikely to comply with the requirements of the trial or any condition that presents undue risk from the investigational product or procedures.
23. Participation in another interventional clinical trial involving an investigational compound within 26 weeks prior to screening or in parallel to this trial.
24. Currently using or have used within the last 3 days prior to screening: biotin \>0.03 mg/day from supplements
25. Known history of positive results of tests for human immunodeficiency virus (HIV) antibodies or hepatitis B and/or C (exceptions if vaccinated towards Hepatitis B virus and Hepatitis C virus).
26. Any of the following: acute critical illness, and complications following open heart surgery, abdominal surgery, multiple accidental traumas, acute respiratory failure, or similar conditions within 180 days prior to screening.

Primary outcomes:
measure: Change From Baseline in Trunk Percent Fat at Week 38
timeFrame: Baseline, Week 38
Secondary outcomes:
measure: Change From Baseline in Total Body Lean Mass at Week 38
timeFrame: Baseline, Week 38
measure: Change From Baseline in Trunk Fat Mass at Week 38
timeFrame: Baseline, Week 38
measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study Discontinuation
timeFrame: Up to 38 weeks
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Ascendis Pharma Investigational Site
state: Alabama
city: Phoenix
country: United States
facility: Ascendis Pharma Investigational Site
state: Arizona
city: Fresno
country: United States
facility: Ascendis Pharma Investigational Site
state: California
city: Los Angeles
country: United States
facility: Ascendis Pharma Investigational Site
state: California
city: Los Angeles
country: United States
facility: Ascendis Pharma Investigational Site
state: California
city: Palo Alto
country: United States
facility: Ascendis Pharma Investigational Site
state: California
city: Torrance
country: United States
facility: Ascendis Pharma Investigational Site
state: California
city: Chicago
country: United States
facility: Ascendis Pharma Investigational Site
state: Illinois
city: Indianapolis
country: United States
facility: Ascendis Pharma Investigational Site
state: Indiana
city: Boston
country: United States
facility: Ascendis Pharma Investigational Site
state: Massachusetts
city: Dearborn
country: United States
facility: Ascendis Pharma Investigational Site
state: Michigan
city: Rochester
country: United States
facility: Ascendis Pharma Investigational Site
state: Minnesota
city: Saint Louis
country: United States
facility: Ascendis Pharma Investigational Site
state: Missouri
city: Las Vegas
country: United States
facility: Ascendis Pharma Investigational Site
state: Nevada
city: Reno
country: United States
facility: Ascendis Pharma Investigational Site
state: Nevada
city: New York
country: United States
facility: Ascendis Pharma Investigational Site
state: New York
city: New York
country: United States
facility: Ascendis Pharma Investigational Site
state: New York
city: Morehead City
country: United States
facility: Ascendis Pharma Investigational Site
state: North Carolina
city: Portland
country: United States
facility: Ascendis Pharma Investigational Site
state: Oregon
city: Pittsburgh
country: United States
facility: Ascendis Pharma Investigational Site
state: Pennsylvania
city: Dallas
country: United States
facility: Ascendis Pharma Investigational Site
state: Texas
city: San Antonio
country: United States
facility: Ascendis Pharma Investigational Site
state: Texas
city: Seattle
country: United States
facility: Ascendis Pharma Investigational Site
state: Washington
city: Yerevan
country: Armenia
facility: Ascendis Pharma Investigational Site
city: Saint Leonards
country: Australia
facility: Ascendis Pharma Investigational Site
state: New South Wales
city: Sydney
country: Australia
facility: Ascendis Pharma Investigational Site
state: New South Wales
city: Box Hill
country: Australia
facility: Ascendis Pharma Investigational Site
state: Victoria
city: Fitzroy
country: Australia
facility: Ascendis Pharma Investigational Site
state: Victoria
city: Parkville
country: Australia
facility: Ascendis Pharma Investigational Site
state: Victoria
city: Perth
country: Australia
facility: Ascendis Pharma Investigational Site
state: Western Australia
city: Vancouver
country: Canada
facility: Ascendis Pharma Investigational Site
state: British Columbia
city: Halifax
country: Canada
facility: Ascendis Pharma Investigational Site
state: Nova Scotia
city: København
country: Denmark
facility: Ascendis Pharma Investigational Site
city: Lyon
country: France
facility: Ascendis Pharma Investigational Site
city: Marseille
country: France
facility: Ascendis Pharma Investigational Site
city: Nantes
country: France
facility: Ascendis Pharma Investigational Site
city: Paris
country: France
facility: Ascendis Pharma Investigational Site
city: Tbilisi
country: Georgia
facility: Ascendis Pharma Investigational Site
city: Tbilisi
country: Georgia
facility: Ascendis Pharma Investigational Site
city: München
country: Germany
facility: Ascendis Pharma Investigational Site
state: Bayern
city: Athens
country: Greece
facility: Ascendis Pharma Investigational Site
state: Attica
city: Athens
country: Greece
facility: Ascendis Pharma Investigational Site
state: Attica
city: Thessaloníki
country: Greece
facility: Ascendis Pharma Investigational Site
state: Central Macedonia
city: Thessaloníki
country: Greece
facility: Ascendis Pharma Investigational Site
city: Beer Sheva
country: Israel
facility: Ascendis Pharma Investigational Site
city: Haifa
country: Israel
facility: Ascendis Pharma Investigational Site
city: Petah Tikva
country: Israel
facility: Ascendis Pharma Investigational Site
city: Tel Aviv
country: Israel
facility: Ascendis Pharma Investigational Site
city: Genova
country: Italy
facility: Ascendis Pharma Investigational Site
city: Rome
country: Italy
facility: Ascendis Pharma Investigational Site
city: Rome
country: Italy
facility: Ascendis Pharma Investigational Site
city: Rozzano
country: Italy
facility: Ascendis Pharma Investigational Site
city: Kobe
country: Japan
facility: Ascendis Pharma Investigational Site
state: Hyogo
city: Kawasaki
country: Japan
facility: Ascendis Pharma Investigational Site
state: Kanagawa
city: Yokohama
country: Japan
facility: Ascendis Pharma Investigational Site
state: Kanagawa
city: Yokohama
country: Japan
facility: Ascendis Pharma Investigational Site
state: Kanagawa
city: Matsumoto
country: Japan
facility: Ascendis Pharma Investigational Site
state: Nagano
city: Kashihara
country: Japan
facility: Ascendis Pharma Investigational Site
state: Nara
city: Ishikawa
country: Japan
facility: Ascendis Pharma Investigational Site
state: Okinawa
city: Suita
country: Japan
facility: Ascendis Pharma Investigational Site
state: Osaka
city: Chiba
country: Japan
facility: Ascendis Pharma Investigational Site
city: Fukuoka
country: Japan
facility: Ascendis Pharma Investigational Site
city: Kagoshima
country: Japan
facility: Ascendis Pharma Investigational Site
city: Kawasaki
country: Japan
facility: Ascendis Pharma Investigational Site
city: Nagakute
country: Japan
facility: Ascendis Pharma Investigational Site
city: Okayama
country: Japan
facility: Ascendis Pharma Investigational Site
city: Osaka
country: Japan
facility: Ascendis Pharma Investigational Site
city: Tokyo
country: Japan
facility: Ascendis Pharma Investigational Site
city: Yamagata
country: Japan
facility: Ascendis Pharma Investigational Site
city: Seoul
country: Korea, Republic of
facility: Ascendis Pharma Investigational Site
city: Seoul
country: Korea, Republic of
facility: Ascendis Pharma Investigational Site
city: Seoul
country: Korea, Republic of
facility: Ascendis Pharma Investigational Site
city: Suwon
country: Korea, Republic of
facility: Ascendis Pharma Investigational Site
city: George Town
country: Malaysia
facility: Ascendis Pharma Investigational Site
city: Kota Bharu
country: Malaysia
facility: Ascendis Pharma Investigational Site
city: Melaka
country: Malaysia
facility: Ascendis Pharma Investigational Site
city: Putrajaya
country: Malaysia
facility: Ascendis Pharma Investigational Site
city: Leiden
country: Netherlands
facility: Ascendis Pharma Investigational Site
city: Palmerston North
country: New Zealand
facility: Ascendis Pharma Investigational Site
state: Manawatu-Wanganui
city: Wellington
country: New Zealand
facility: Ascendis Pharma Investigational Site
city: Kraków
country: Poland
facility: Ascendis Pharma Investigational Site
city: Poznań
country: Poland
facility: Ascendis Pharma Investigational Site
city: Warsaw
country: Poland
facility: Ascendis Pharma Investigational Site
city: Wrocław
country: Poland
facility: Ascendis Pharma Investigational Site
city: Łódź
country: Poland
facility: Ascendis Pharma Investigational Site
city: Bucharest
country: Romania
facility: Ascendis Pharma Investigational Site
city: Iaşi
country: Romania
facility: Ascendis Pharma Investigational Site
city: Timişoara
country: Romania
facility: Ascendis Pharma Investigational Site
city: Belgrade
country: Serbia
facility: Ascendis Pharma Investigational Site
city: Kragujevac
country: Serbia
facility: Ascendis Pharma Investigational Site
city: Bratislava
country: Slovakia
facility: Ascendis Pharma Investigational Site
city: Lubochna
country: Slovakia
facility: Ascendis Pharma Investigational Site
city: Alicante
country: Spain
facility: Ascendis Pharma Investigational Site
city: Barcelona
country: Spain
facility: Ascendis Pharma Investigational Site
city: Barcelona
country: Spain
facility: Ascendis Pharma Investigational Site
city: Madrid
country: Spain
facility: Ascendis Pharma Investigational Site
city: Santiago De Compostela
country: Spain
facility: Ascendis Pharma Investigational Site
city: Sevilla
country: Spain
facility: Ascendis Pharma Investigational Site
city: Ankara
country: Turkey
facility: Ascendis Pharma Investigational Site
city: Antalya
country: Turkey
facility: Ascendis Pharma Investigational Site
city: Aydın
country: Turkey
facility: Ascendis Pharma Investigational Site
city: İzmir
country: Turkey
facility: Ascendis Pharma Investigational Site
city: İzmit
country: Turkey
facility: Ascendis Pharma Investigational Site
city: Kayseri
country: Turkey
facility: Ascendis Pharma Investigational Site
city: Ivano-Frankivs'k
country: Ukraine
facility: Ascendis Pharma Investigational Site
city: Kharkiv
country: Ukraine
facility: Ascendis Pharma Investigational Site
city: Kyiv
country: Ukraine
facility: Ascendis Pharma Investigational Site
city: Kyiv
country: Ukraine
facility: Ascendis Pharma Investigational Site
city: Kyiv
country: Ukraine
facility: Ascendis Pharma Investigational Site
city: Vinnytsya
country: Ukraine
facility: Ascendis Pharma Investigational Site
city: Cardiff
country: United Kingdom
facility: Ascendis Pharma Investigational Site
city: Coventry
country: United Kingdom
facility: Ascendis Pharma Investigational Site
city: Leeds
country: United Kingdom
facility: Ascendis Pharma Investigational Site
Study officials:
References: